34 In the index

Pyrilutamide

An experimental topical treatment for male pattern hair loss, designed to work locally on the scalp without much absorption into the rest of the body. Human trials done in China show it reduces hair loss with good overall safety, though it remains unapproved outside of trials.

Effects Hormonal

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; investigational

Reported range Phase III trial doses (topical, hair loss): 1-2 applications daily of the studied concentration

Route Topical

Frequency Once or twice daily (trial protocol)

Duration Trial durations of 6 months or more

An investigational topical androgen-receptor antagonist for androgenetic alopecia (also studied for acne), in late-stage trials primarily in China; not an approved product outside that context.

Where this comes from Published Phase III clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.